Breast Cancer Market in Southeast Asia “to hit $2.7 billion by 2022”

April 13, 2017

According to business intelligence provider GBI Research, the Southeast Asian breast cancer market-covering South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia-is expected to increase 16.2% from $942.3 million in 2015 to $2.7 billion in 2022

According to business intelligence provider GBI Research, the Southeast Asian breast cancer market-covering South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia-is expected to increase 16.2% from $942.3 million in 2015 to $2.7 billion in 2022

GBI’s latest report suggests that the driving force for growth can be ascribed to an increase in diagnosed prevalence, and the annual cost of therapy due to higher uptake of costlier drugs.

Presently, the breast cancer market consists of chemotherapies, hormonal therapies, and targeted therapies. Herceptin is the gold standard monoclonal antibody for the treatment of human epidermal growth factor receptor (HER) 2-positive disease, and is prescribed in nearly all settings. Although it is available across Southeast Asia, its use is limited in most countries due to affordability issues and limitations surrounding the diagnosis of HER2 status.